-
-
-
-
-
-
-
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
BioCryst raises ORLADEYO drug price by 9% starting January 2026
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on BioCryst Pharma (BCRX)
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Announces Sale of European ORLADEYO Business to Neopharmed Gentili for up to $264 Million
-
-
-
-
-
-
-
Pre-Open Stock Movers 02/18: (LM) (BEN) (AAP) Higher; (FLR) (CAG) (CVU) Lower (more...)
-
-
-
-
-
-
-
BioCryst Reports First Quarter 2019 Financial Results
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Update on Strategy, Pipeline and Outlook
-
1,180,150 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

